Retatrutide: Metabolic Trial Data

Retatrutide (developmental name LY3437943) is a synthetic peptide under development by Eli Lilly and Company that simultaneously activates three G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). A single molecule combines these three receptor activities; the clinical effect cannot be assigned to one receptor from a weight-loss result alone.

As of October 9, 2026, retatrutide remains investigational and not FDA-approved. This review separates peer-reviewed Phase II metabolic findings from later sponsor-reported Phase III results. FDA also states that retatrutide cannot be used in compounding under federal law. []

For context on how Phase II data differs from Phase III evidence, see Understanding Clinical Trials for Peptide Drugs.

The Rationale for Adding Glucagon Receptor Activity

To understand why Lilly added glucagon receptor agonism to an already-active GIP/GLP-1 dual agonist like tirzepatide, it is necessary to understand what glucagon does beyond its classical role in raising blood glucose.

Glucagon's metabolic roles beyond glycemia:

• Energy expenditure: Glucagon receptor signaling is one proposed contributor to energy expenditure. Preclinical findings support investigating this mechanism, but do not establish the size of its independent contribution in humans. []
• Hepatic fat reduction: Glucagon receptor agonism has been associated with reduced hepatic steatosis (liver fat) in animal models, which is relevant for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD).
• Satiety signaling: Glucagon may contribute to appetite suppression through central nervous system pathways.

These properties suggested that adding glucagon receptor activity to GLP-1R/GIPR agonism might further increase weight loss — particularly through energy expenditure — beyond what dual agonism achieves.

The challenge: Glucagon classically raises blood glucose. In people with diabetes, glucagon receptor activation is typically counterproductive. Retatrutide's Phase II program studied people with obesity without diabetes and people with type 2 diabetes in separate trials, to characterize the safety and efficacy profile in each population.

Phase II Trial Results (NEJM, 2023)

The Phase II data for retatrutide was published in the New England Journal of Medicine in 2023 by Jastreboff et al.[] This historical trial provides a peer-reviewed foundation for the obesity findings discussed here; it is not the entire current development record.

The trial enrolled 338 adults with obesity (BMI ≥27 with comorbidity or ≥30) without diabetes, randomized to placebo or retatrutide at 1mg, 4mg, 8mg, or 12mg weekly over 48 weeks.

Reported research outcomes at 48 weeks:

Dose	Mean Weight Change	% Achieving ≥15% Loss
Placebo	−2.1%	2%
Retatrutide 4mg (combined groups)	−17.1%	60%
Retatrutide 8mg (combined groups)	−22.8%	75%
Retatrutide 12mg	−24.2%	83%

The highest studied group had a 24.2% mean reduction at 48 weeks. This is a group average, not an expected individual outcome. The table describes trial assignments rather than a treatment schedule. []

Important caveats for interpreting these numbers:

• Phase II trials are not powered to detect all adverse events
• The trial duration (48 weeks) differs from the semaglutide and tirzepatide trials used for comparison
• Patient populations and entry criteria differ across trials — indirect comparisons are hypothesis-generating, not definitive
• Phase II results frequently change, sometimes substantially, when Phase III trials are conducted in larger, more diverse populations

Molecular Design

The preclinical characterization of LY3437943 was described by Coskun et al. (2022).[]

Retatrutide is a 36-amino acid peptide based on a GIP sequence scaffold, modified to achieve balanced activity across all three receptors. Key features:

• Triple receptor activity: The molecule activates GIP, GLP-1, and glucagon receptors, with potency differing by receptor and assay; the activities are not interchangeable. []
• C20 fatty diacid modification: Enables albumin binding for extended half-life (~6 days), supporting once-weekly dosing
• DPP-4 resistance: Structural modifications protect against the rapid N-terminal cleavage that inactivates native GLP-1

The preclinical Cell Metabolism paper provided proof-of-concept in rodent models, demonstrating that the triple agonist produced greater reductions in body weight and liver fat than GLP-1R/GIPR dual agonism alone.

Retatrutide and Its Effects on Metabolic Parameters

Weight is only one measured outcome. Researchers also assess blood glucose, liver fat, and markers associated with insulin sensitivity and lipid metabolism.

Parameter	Human evidence	How to interpret it
Body weight	Randomized Phase II obesity trial, 338 adults, 48 weeks	A treatment-group average in a selected population
HbA1c	Separate Phase II type 2 diabetes trial, 281 participants	A measure of average blood glucose; not an outcome from the non-diabetic obesity trial
Liver fat	MRI-based substudy, 98 participants with elevated baseline liver fat	An imaging endpoint, not proof of fewer liver complications
Insulin sensitivity and lipids	Exploratory analyses in the liver-fat substudy	Changes associated with reduced liver fat and weight; do not establish independent causation

The diabetes trial reported improved glycemic control as well as weight reduction. The primary HbA1c endpoint was measured at 24 weeks, while bodyweight and additional glycemic outcomes were followed to 36 weeks. Those results should not be pooled with the 48-week obesity trial. []

In the liver-fat substudy, the highest studied group had an 82.4% relative reduction in liver fat at 24 weeks, compared with a 0.3% increase with placebo. Relative reduction differs from a percentage-point change in liver fat concentration. Changes in liver fat were associated with changes in weight and metabolic measures, including insulin sensitivity and lipid metabolism. []

The substudy was small and selected participants with at least 10% liver fat at baseline. Its imaging and biomarker findings do not prove reduced cirrhosis, cardiovascular events, or mortality. For the biological context, see GLP-1, GIP, and glucagon receptor mechanisms.

Phase III Status and FDA Approval

TRIUMPH-1 is registered as NCT05929066. A registry describes a study's design and status; it should not be mistaken for a complete results publication. []

On July 23, 2026, Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3. It reported weight and HbA1c improvements in the diabetes population and weight reductions in participants with established cardiovascular disease. The announcement said detailed results would be presented and published later, and described a planned U.S. submission in the first quarter of 2027. These are sponsor-reported results and plans, not an approval decision. []

Study populations, follow-up periods, and statistical estimands differ. An estimand defines which treatment effect a trial is trying to estimate, including how treatment discontinuation is handled. Readers should compare results using that context rather than combine headline percentages from different trials.

FDA continues to identify retatrutide as unapproved. A submission plan does not establish an approval date, final indication, or prescribing label. []

Safety Profile and Evidence Limits

Gastrointestinal adverse events were the most common events in the Phase II obesity study, generally mild to moderate and related to the studied dose. Increases in heart rate peaked around 24 weeks and declined afterward. These findings require interpretation alongside participant withdrawals and the full trial report. []

A trial with 338 participants cannot reliably characterize every rare adverse event or long-term risk. The absence of a particular event in a short study is not evidence that the event cannot occur.

Retatrutide has no FDA-approved prescribing label. Its receptor activity does not establish that every warning or contraindication for an approved GLP-1 medicine applies identically. The semaglutide research review describes an approved medicine with a different regulatory evidence base.

Comparison with Semaglutide and Tirzepatide

Semaglutide activates GLP-1 receptors, tirzepatide activates GIP and GLP-1 receptors, and retatrutide adds glucagon receptor activity. A greater number of receptor targets does not by itself prove better clinical outcomes.

The Phase II retatrutide studies discussed above did not establish superiority over semaglutide or tirzepatide in a direct head-to-head obesity comparison. Trial duration, population, endpoints, and handling of missing data affect the results. Our three-compound comparison and guide to evaluating research claims explain why indirect comparisons require caution.

Frequently Asked Questions

What metabolic parameters have retatrutide trials measured?

Human studies have assessed body weight, HbA1c, liver fat, and exploratory insulin-sensitivity and lipid measures. These outcomes come from different populations and studies, so they should be interpreted separately.

Does reduced liver fat prove retatrutide prevents liver disease complications?

No. MRI liver fat and biomarkers are surrogate outcomes. The small Phase II substudy does not establish prevention of cirrhosis, liver failure, or death.

Is retatrutide FDA-approved?

No. FDA identifies retatrutide as an unapproved drug. Sponsor announcements and a planned regulatory submission do not change that status.

Is retatrutide proven better than semaglutide or tirzepatide?

The studies summarized here do not establish that claim. Direct comparisons with appropriate populations, endpoints, and safety follow-up are needed.